Latest news with #ArteraAI
Forbes
8 hours ago
- Health
- Forbes
How AI Is Helping Cancer Patients: Saving Lives And Money
Medical technology concept. Medical doctor. getty Cancer treatment is costly. The average cost of cancer care in the U.S. is around $150,000 per patient—more than four times the cost of treatment for other common health conditions, according to AARP. The American Cancer Society projected that In 2025, more than 2 million people in the U.S. are expected to be diagnosed with cancer, with over 618,000 deaths projected. With these high costs, artificial intelligence (AI) is offering new solutions that are not only saving lives but also making cancer care more affordable. Early detection is one of the most effective ways to reduce cancer treatment costs. When cancer is caught in its earliest stages, treatments tend to be less aggressive and more affordable. At The Christ Hospital, AI has significantly improved lung cancer detection. 'Nearly 70% of lung cancer cases are now found at stage I or II, well above the national average of 46%,' said Seth Howard, executive vice president of research and development at Epic. 'In just six months, over 60 patients started treatment earlier, significantly improving their chances of survival.' By diagnosing cancer earlier, AI allows doctors to offer more cost-effective treatment options, which helps lower the financial burden on both patients and healthcare systems. ArteraAI is another example of how AI is transforming cancer care. Their AI technology is helping doctors determine which cancer treatments are best for their patients, preventing unnecessary therapies. 'AI is the most transformative tech we've had in a long time,' said Andre, founder of Artera. 'The impact AI has had on the healthcare system is as powerful as computers have had on the healthcare system. With the ArteraAI Prostate Test, we can personalize treatments, reducing unnecessary costs while improving outcomes.' The ArteraAI Prostate Test is fully reimbursed by Medicare under its established payment rate, meaning no out-of-pocket costs for eligible Medicare patients. This makes prostate cancer care more affordable and reduces financial strain during treatment. Surgery is often a key part of cancer treatment. Proprio, a company that has developed AI-powered surgical technology, provides surgeons with real-time data during operations, reducing the need for traditional imaging like CT scans and X-rays. This technology allows for faster surgeries, less strain on hospital staff, and quicker recovery times, which ultimately lowers the cost of care for patients. Another breakthrough demonstrating AI's transformative potential in cancer care is AION Biosystems' TempShield device. A recent study showed that TempShield, an AI-powered wearable thermometer for oncology patients, can reduce mortality rates by an astonishing 90% among cancer patients undergoing chemotherapy and inpatient hospital stays by 79%. This innovation addresses a crucial, yet often overlooked, fact: more than 50% of cancer deaths are preventable because they result from infections like pneumonia rather than cancer itself. If you spot a temperature spike (and hence an infection) early and treat it, you save lives. TempShield's continuous temperature monitoring provides clinicians with alerts up to 72 hours before symptoms of infection appear, enabling earlier intervention. 'The real danger in cancer care isn't just the disease—it's the complications we miss,' said Sam Barend, CEO of AION Biosystems. 'TempShield is a game-changer: small, simple, and affordable, and it's helping save lives by catching infections before symptoms appear—just like the blood glucose monitor did for diabetes.' AI is revolutionizing cancer care, not only improving outcomes but also making treatment more affordable. Early detection, personalized treatment, and more efficient surgeries all contribute to lowering the financial burden on patients while providing better care. With innovations like the ArteraAI Prostate Test and TempShield, AI is making cancer care smarter, more accessible, and more cost-effective for patients across the globe. As AI technologies continue to evolve, they will undoubtedly play an even greater role in both saving lives and reducing the financial strain of cancer treatment.
Yahoo
30-05-2025
- Business
- Yahoo
ASCO25: AI test shown to aid in prostate cancer treatment planning
New research has demonstrated that an AI-based test developed by US-based Artera can help identify which men with non-metastatic high-risk prostate cancer are most likely to benefit from being administered abiraterone. Abiraterone (Zytiga) is an androgen deprivation therapy (ADT) used in men with metastatic castration-resistant prostate cancer (mCRPC) that no longer responds to standard hormone therapy. The ArteraAI test assesses prostate needle biopsy images to provide risk stratification and prediction of the benefits of ADT for prostate cancer patients. Researchers from the UK's Institute of Cancer Research (ICR) and University College London (UCL) applied the test to biopsy images from more than 1,000 men who took part in the Stampede trial (NCT00268476), coordinated by the Medical Research Council (MRC) Clinical Trials Unit at UCL and funded by Cancer Research UK. ArteraAI helped identify that 25% of men with high-risk prostate cancer from the Stampede trial who would most likely benefit from receiving abiraterone. For those patients with biomarker-positive tumours, abiraterone cut the risk of death after five years from 17% to 9%. Full details of the study will be shared during a presentation at the American Society of Clinical Oncology (ASCO) 2025 meeting, taking place from 30 May to 3 June in Chicago, Illinois. Nick James, professor of prostate and bladder cancer research at the Institute of Cancer Research and consultant clinical oncologist at the Royal Marsden NHS Foundation Trust, served as chief investigator on the STAMPEDE and is co-leader of the current research. James noted that since abiraterone comes with potential side effects that may require additional monitoring, such as potential issues with high blood pressure and liver abnormalities, knowing who is most likely to benefit is 'very valuable'. He said: 'This research shows that we can pick out the people who will respond best to abiraterone, and those who will do well from standard treatment alone – hormone therapy and radiotherapy.' Abiraterone is indicated for use on the UK National Health Service (NHS) in England for patients with advanced prostate cancer that has come back and spread to other parts of the body, but not for patients newly diagnosed with high-risk prostate cancer that has not yet spread. However, abiraterone has been available for men with this indication in Scotland and Wales for two years. The study's co-lead UCL Cancer Institute professor Gert Attard commented: 'This study shows, in a very large cohort of patients, that novel algorithms can be used to extract information from routinely available pathology slides to tailor these treatments to specific patients and minimise over-treatment while maximising the chance of cure." "ASCO25: AI test shown to aid in prostate cancer treatment planning" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
30-05-2025
- Business
- Yahoo
ASCO25: AI test shown to aid in prostate cancer treatment planning
New research has demonstrated that an AI-based test developed by US-based Artera can help identify which men with non-metastatic high-risk prostate cancer are most likely to benefit from being administered abiraterone. Abiraterone (Zytiga) is an androgen deprivation therapy (ADT) used in men with metastatic castration-resistant prostate cancer (mCRPC) that no longer responds to standard hormone therapy. The ArteraAI test assesses prostate needle biopsy images to provide risk stratification and prediction of the benefits of ADT for prostate cancer patients. Researchers from the UK's Institute of Cancer Research (ICR) and University College London (UCL) applied the test to biopsy images from more than 1,000 men who took part in the Stampede trial (NCT00268476), coordinated by the Medical Research Council (MRC) Clinical Trials Unit at UCL and funded by Cancer Research UK. ArteraAI helped identify that 25% of men with high-risk prostate cancer from the Stampede trial who would most likely benefit from receiving abiraterone. For those patients with biomarker-positive tumours, abiraterone cut the risk of death after five years from 17% to 9%. Full details of the study will be shared during a presentation at the American Society of Clinical Oncology (ASCO) 2025 meeting, taking place from 30 May to 3 June in Chicago, Illinois. Nick James, professor of prostate and bladder cancer research at the Institute of Cancer Research and consultant clinical oncologist at the Royal Marsden NHS Foundation Trust, served as chief investigator on the STAMPEDE and is co-leader of the current research. James noted that since abiraterone comes with potential side effects that may require additional monitoring, such as potential issues with high blood pressure and liver abnormalities, knowing who is most likely to benefit is 'very valuable'. He said: 'This research shows that we can pick out the people who will respond best to abiraterone, and those who will do well from standard treatment alone – hormone therapy and radiotherapy.' Abiraterone is indicated for use on the UK National Health Service (NHS) in England for patients with advanced prostate cancer that has come back and spread to other parts of the body, but not for patients newly diagnosed with high-risk prostate cancer that has not yet spread. However, abiraterone has been available for men with this indication in Scotland and Wales for two years. The study's co-lead UCL Cancer Institute professor Gert Attard commented: 'This study shows, in a very large cohort of patients, that novel algorithms can be used to extract information from routinely available pathology slides to tailor these treatments to specific patients and minimise over-treatment while maximising the chance of cure." "ASCO25: AI test shown to aid in prostate cancer treatment planning" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Time Magazine
08-05-2025
- Health
- Time Magazine
Andre Esteva
Andre Esteva is pioneering a future where AI can personalize therapies to improve health. 'Doctors are the first to tell you they could use help with this,' Esteva says. The company he co-founded and leads as CEO, ArteraAI, has created an AI tool that predicts which prostate cancer treatment will work best for a patient. Prostate cancer is the second-most common cancer in men, and Esteva's efforts became personal last year when his co-founder died of cancer at age 48. The AI is trained on images of tumors—detailed at the cellular level from more than 100,000 patients—and compares these patterns to an individual patient's images to choose the right treatment option. The AI uses some additional patient information, but '98% of the signal comes from the tumor images,' Esteva says. In 2024, the National Comprehensive Cancer Network, a nonprofit group of cancer centers that develops best practice guidelines, recommended the tool to cancer clinicians in the U.S., and ArteraAI has already helped nearly 20% of these clinicians integrate it into patient care, Esteva says. The tool was approved for Medicare reimbursement last year, and Esteva expects it will work for other cancer types in the next 12-18 months. 'It will save many lives,' Esteva says.
